James Eshelby Senior Director WWBD - PowerPoint PPT Presentation

Title: James Eshelby Senior Director WWBD


1
James EshelbySenior DirectorWWBD
Partnering Pharmas Perspective
2
Overview

• Role of WWBD
• Search Evaluation
• Negotiation
• Alliance Management
• Open Innovation
• Business models

3
Pressures Driving Change
2. Price Controls on Pharmaceuticals
1. Productivity
4. Financial Markets
3. Patent Expirations
4
Innovation is challenging!
Anti-counterfeiting
Biomarkers
NDA/MMA
Indications Discovery
Market
Full Development
Registration
Delivery device
CAN-generating
Formulations
PharmSci scale-up
Imaging studies
ADME / PDM
Exploratory Development
Drug Pfinder
Toxicogenomics
Process Chemistry
Safety models
Predictive modeling
Synthesis services
Discovery
Idea
5
Partnerships are a key source of diversity and
innovation
WWBD Bill Ringo

• Building RD Engine
• Technology access
• Research collaborations

• Product Opportunities
• POC - Commercial

• Strategic Alliances
• Search and Evaluation
• Contract Negotiation
• Alliance Management

Search and Evaluation
Transactions
Alliance Management
6
Alliance Board
7
Success Factors

• Quality Science matches Strategic objective
• Pick a partner who you can work with for the long
  haul
• Ensure clarity of expected activities and
  outcomes
• Ensure mutual benefit and the contract reflects
  alliance

8
Realising Value

• Signing a deal is not in itself a success

Were in a risky businessSuccess can never be
guaranteedBut we can act to tilt the odds
Alliance Management has become critical
9
Alliance Management Maximising Chances of
Success
Relationships and Trust
Open Communication at All Levels
What is Best for the Product

Effective Governance and Decision Making
Apply Appropriate Resources

Key Success Drivers
Trust, Transparency, Flexibility
10
Open to Open Innovation

• We intend to make our internal capability even
  more effective by tapping into the best
  scientific capability outside of our
  walls-wherever it exists. Thats why we are
  reaching out to scientists around the world.
• -Jeff Kindler
• Pfizer Chairman CEO
• 2007

11
So Can Pharma Afford to Embrace Open Innovation?
12
So Can Pharma Afford to Embrace Open Innovation?
13
So what is Open Innovation?
Closed Innovation
Open Innovation
Fuzzy Front-End
Development
Commercialization

• If we make the most of internal and external
  ideas we will win
• Not all the smart people work for us
• We should profit from others use of our IP we
  should buy IP when advantageous

• If we create the most and best ideas in the
  industry we will win
• The smartest people work for us
• We must control our IP so that competitors dont
  profit from it

14
How we Managed IPR
WE Control

• IPR

15
How to Manage IPR
We Control
Exclusive Licences
Joint Exploitation

• IPR

Non-Exclusive Licences
Publish
16
Deal Structures
What do we / you really need?
17
Success from Open Access IP comes from all
parties gaining as well as giving
Academia
SME
Pharma
IP
Efficacy/ safety info Faster development to market
New research directions/publications Access to
chemical tools/technology Spin out potential
Validation of technology Application to Drug
disc/dev programs Attractiveness to money markets
18
Collaboration is key to success

• Contract Research

• Request For Proposals

Consortia

• DrugPfinder

• Collaborative RD
• Agreement

• The Pfizer Incubator

• Venture Investment

Public-Private Partnerships
19
Deals Becoming More Varied

• Collaborative Research

• Scripps
• University of Cambridge.

• Joint Exploitation

• Bend Research

• Consortia

• Dundee Kinase collaboration
• University of Dundee, Pfizer, GSK, AZ, Merck
  Co, BI, Merck KGaA
• Innovative Medicines Initiative
• UK Stem Cell for Safer Medicine

• PPP

.. Equity Venture JVs Options MA
20

• Thanks for your attention!
• Submit your idea at
• http//www.pfizer.com/partnering